We are live on ! Find out more
ACA

Acorn Capital Advisors Portfolio holdings

AUM $366M
1-Year Est. Return 474.6%
This Fund
S&P 500
This Quarter Est. Return
+48.27%
1 Year Est. Return
+474.6%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$366M
AUM Growth
+$14.6M
Cap. Flow
-$74.2M
Cap. Flow %
-20.25%
Top 10 Hldgs %
90.19%
Holding
23
New
1
Increased
5
Reduced
3
Closed
3

Top Buys

Rank Stock Value
1
KPTI icon
Karyopharm Therapeutics
KPTI
+$10.7M
2
ENGN icon
enGene Therapeutics
ENGN
+$5.18M
3
JBIO
Jade Biosciences
JBIO
+$4.17M
4
AURA icon
Aura Biosciences
AURA
+$2.38M
5
CGON icon
CG Oncology
CGON
+$65.3K

Top Sells

Rank Stock Value
1
TERN
Terns Pharmaceuticals
TERN
+$92.1M
2
CRDF icon
Cardiff Oncology
CRDF
+$2.85M
3
XFOR icon
X4 Pharmaceuticals
XFOR
+$967K
4
QTTB icon
Q32 Bio
QTTB
+$826K
5
BCAX
Bicara Therapeutics
BCAX
+$22

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$6.67B
$80.4M 21.94%
1,131,500
+999
+0.1% +$65.3K
URGN icon
2
UroGen Pharma
URGN
$2.17B
$61.6M 16.8%
1,673,420
– –
TRVI icon
3
Trevi Therapeutics
TRVI
$2.19B
$40M 10.92%
2,144,844
– –
CADL icon
4
Candel Therapeutics
CADL
$862M
$36M 9.83%
3,497,948
– –
PBYI icon
5
Puma Biotechnology
PBYI
$493M
$33.5M 9.14%
4,131,299
– –
JBIO
6
Jade Biosciences
JBIO
$1.09B
$21.9M 5.98%
986,760
+200,000
+25% +$4.17M
BCAX
7
Bicara Therapeutics
BCAX
$1.51B
$19.1M 5.21%
643,381
-1
-0% -$22
KPTI icon
8
Karyopharm Therapeutics
KPTI
$38.6M
$14.8M 4.05%
1,518,113
+1,230,287
+427% +$10.7M
OKUR
9
OnKure Therapeutics
OKUR
$120M
$12.9M 3.53%
2,839,674
– –
HELP
10
Cybin Inc
HELP
$988M
$10.2M 2.78%
1,540,266
– –
TARA icon
11
Protara Therapeutics
TARA
$216M
$6.69M 1.83%
1,752,115
– –
AURA icon
12
Aura Biosciences
AURA
$692M
$6.6M 1.8%
929,077
+333,333
+56% +$2.38M
LONA
13
LeonaBio Inc
LONA
$63.3M
$5.83M 1.59%
634,539
– –
VSTM icon
14
Verastem
VSTM
$693M
$5.61M 1.53%
1,469,153
– –
WHWK
15
Whitehawk Therapeutics
WHWK
$234M
$5.22M 1.42%
1,139,363
– –
QTTB icon
16
Q32 Bio
QTTB
$326M
$2.75M 0.75%
216,171
-98,881
-31% -$826K
ENGN icon
17
enGene Therapeutics
ENGN
$127M
$2.2M 0.6%
+1,271,257
New +$5.18M
JSPR icon
18
Jasper Therapeutics
JSPR
$20.2M
$604K 0.16%
1,438,159
+26,667
+2% +$20K
BCAB
19
DELISTED
BIOATLA INC
BCAB
$448K 0.12%
108,126
-1
-0% -$4
YARW
20
Yarrow Bioscience
YARW
$72.4M
$926 ﹤0.01%
29
– –
CRDF icon
21
Cardiff Oncology
CRDF
$99.6M
– –
-1,762,084
Closed -$2.85M
TERN
22
DELISTED
Terns Pharmaceuticals
TERN
– –
-1,746,264
Closed -$92.1M
XFOR icon
23
X4 Pharmaceuticals
XFOR
$343M
– –
-234,039
Closed -$967K

Similar funds

WA
Waterford Advisors Orchard Park, New York $366M AUM 19.27% 1-Year Est. Return
ICP
Impact Capital Partners Greenwood Village, Colorado $367M AUM 28.36% 1-Year Est. Return
CIC
Concord Investment Counsel Irvine, California $366M AUM 38.82% 1-Year Est. Return
SA
SAM Advisors Oakhurst, California $366M AUM 19.93% 1-Year Est. Return
PLC
Pillsbury Lake Capital San Francisco, California $366M AUM
FIBOI
First International Bank of Israel Tel Aviv $367M AUM 14.87% 1-Year Est. Return
SCP
Silverleafe Capital Partners Germantown, Tennessee $367M AUM 37.49% 1-Year Est. Return
VST
Van Strum & Towne San Francisco, California $367M AUM 19.6% 1-Year Est. Return

Acorn Capital Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Acorn Capital Advisors held 23 positions worth $366M, up 4.2% from $352M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

Acorn Capital Advisors withdrew a net $74.2M in Q2 2026, closing 3 positions and reducing 3 holdings. Its most notable exit was Terns Pharmaceuticals, an estimated $92.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Acorn Capital Advisors opened a new position in enGene Therapeutics worth $2.2M.

  • Acorn Capital Advisors's largest Q2 2026 buy was enGene Therapeutics: 1,271,257 shares worth $2.2M.
  • Acorn Capital Advisors added most to Karyopharm Therapeutics in Q2 2026, an estimated $10.7M increase.
  • Acorn Capital Advisors's biggest Q2 2026 reduction was Q32 Bio, cutting an estimated $826K.
  • Acorn Capital Advisors fully exited Terns Pharmaceuticals in Q2 2026, selling an estimated $92.1M.
  • Acorn Capital Advisors's ten largest holdings make up 90% of its $366M portfolio in Q2 2026.
  • Acorn Capital Advisors opened 1 new position and closed 3 in Q2 2026.
  • Acorn Capital Advisors's portfolio value rose 4.2% quarter-over-quarter to $366M.

Based on Acorn Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.